Ginkgo Bioworks Holdings Inc. (NYSE:DNA) Q3 2023 Results Conference Call November 8, 2023 5:30 PM ET
Company Participants
Megan LeDuc - Manager of Investor Relations
Jason Kelly - Founder, CEO & Director
Mark Dmytruk - Chief Financial Officer
Conference Call Participants
Tejas Savant - Morgan Stanley
Poon Mah - TD Cowen
Derik Bruin - BofA Securities
Michael Freeman - Raymond James
E.V. Koslosky - Goldman Sachs
Megan LeDuc
Good evening. I'm Megan LeDuc, Manager of Investor Relations at Ginkgo Bioworks. I'm joined by Jason Kelly, our Co-Founder and CEO; and Mark Dmytruk, our CFO. Thanks, as always, for joining us. We're looking forward to updating you on our progress.
As a reminder, during the presentation today, we'll be making forward-looking statements, which involve risks and uncertainties. Please refer to our filings with the Securities and Exchange Commission to learn more about these risks and uncertainties.
Today, in addition to updating you on the quarter, we're going to dive deeper into a few case studies of how we're seeing our mission to make biology easier to engineer, come to life as well as provide further details on our diverse program pipeline and the growth opportunities we see in biosecurity business. As usual, we'll end with the Q&A session, and I'll take questions from analysts, investors and the public. You can submit those questions to us in advance via Twitter at #GinkgoResults or e-mail us at investors@ginkgobioworks.com.
All right. Over to you, Jason.
Jason Kelly
I'm super excited to be chatting with you all today. I always start with a reminder that our mission at Ginkgo is to make biology easier to engineer. As we dig into the strategic section, you'll see the progress we're making on that mission, particularly with our AI efforts and our strong pipeline of active programs.
We pursue this mission on behalf of a diverse group of customers. This is one of my favorite slides, having a customer list that ranges from agriculture to consumer goods, to chemicals to therapeutics is common for a horizontal tech platform, but it's pretty unique in biotech. It makes sense because all these diverse programs benefit from the scaling of the same underlying technology at Ginkgo.
We've added programs with several new customers this quarter, including smaller companies like Nosh Biofoods in the industrial biotech field and Exacta Biosciences in the ag space, as well as large companies like Pfizer in pharma in addition to new programs with many of our existing customers.